Choosing the Best First-line Therapy: NSCLC with No Actionable Oncogenic Driver

Overview

Journal Lung Cancer Manag

Date 2020 Aug 11

PMID 32774467

Citations 14

Authors

So Yeon Kim

Balazs Halmos

Affiliations

Soon will be listed here.

Abstract

Combination platinum-based therapy has been the standard of care for the treatment of advanced non-small-cell lung cancer (NSCLC). Immunotherapy has emerged and demonstrated to show benefit in the treatment of patients with advanced NSCLC. In this review, we discuss the pivotal trials that led to the US FDA approval of specific immunotherapy regimens in particular patient populations. We discuss the optimal use of immunotherapy as monotherapy based on the KEYNOTE-024, KEYNOTE-042 and IMpower110 trials, chemo-immunotherapy based on KEYNOTE-189, KEYNOTE-407, IMpower150 and IMpower130 trials, and as doublet immunotherapy based on CheckMate-227. We also discuss the role and limitations of PD-L1 expression and tumor mutational burden as predictive biomarkers in response to single-agent immunotherapy and combination chemoimmunotherapy. Furthermore, we discuss emerging resistance markers such as and mutations in immunotherapy response and briefly discuss the role of immunotherapy in elderly patients and in patients with actionable mutations.

Citing Articles

Cost-effectiveness models of non-small cell lung cancer: A systematic literature review.

Willis M, Nilsson A, Lwin Z, Bradvik G, Prelaj A J Manag Care Spec Pharm. 2025; 31(1):69-81.

PMID: 39745843 PMC: 11697584. DOI: 10.18553/jmcp.2025.31.1.69.

Real-World Prevalence, Treatment Patterns, and Outcomes for Patients With HER2 (ERBB2)-Mutant Metastatic Non-Small Cell Lung Cancer, From a US-Based Clinico-Genomic Database.

Waliany S, Nagasaka M, Park L, Lam C, Jiang Z, Lin F Cancer Med. 2024; 13(24):e70272.

PMID: 39692700 PMC: 11653943. DOI: 10.1002/cam4.70272.

A first-in-human phase I study of the PD-1 inhibitor, retifanlimab (INCMGA00012), in patients with advanced solid tumors (POD1UM-101).

Lakhani N, Cosman R, Banerji U, Rasco D, Tomaszewska-Kiecana M, Garralda E ESMO Open. 2024; 9(4):102254.

PMID: 38387109 PMC: 11076959. DOI: 10.1016/j.esmoop.2024.102254.

Advances and challenges of first-line immunotherapy for non-small cell lung cancer: A review.

Guo H, Zhang J, Qin C, Yan H, Luo X, Zhou H Medicine (Baltimore). 2024; 103(3):e36861.

PMID: 38241591 PMC: 10798763. DOI: 10.1097/MD.0000000000036861.

Hot and cold tumors: Immunological features and the therapeutic strategies.

Wang L, Geng H, Liu Y, Liu L, Chen Y, Wu F MedComm (2020). 2023; 4(5):e343.

PMID: 37638340 PMC: 10458686. DOI: 10.1002/mco2.343.

References

Socinski M, Jotte R, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N . Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med. 2018; 378(24):2288-2301. DOI: 10.1056/NEJMoa1716948. View

Mazieres J, Drilon A, Lusque A, Mhanna L, Cortot A, Mezquita L . Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol. 2019; 30(8):1321-1328. PMC: 7389252. DOI: 10.1093/annonc/mdz167. View

Skoulidis F, Goldberg M, Greenawalt D, Hellmann M, Awad M, Gainor J . Mutations and PD-1 Inhibitor Resistance in -Mutant Lung Adenocarcinoma. Cancer Discov. 2018; 8(7):822-835. PMC: 6030433. DOI: 10.1158/2159-8290.CD-18-0099. View

Reck M, Mok T, Nishio M, Jotte R, Cappuzzo F, Orlandi F . Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med. 2019; 7(5):387-401. DOI: 10.1016/S2213-2600(19)30084-0. View

Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gumus M, Mazieres J . Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med. 2018; 379(21):2040-2051. DOI: 10.1056/NEJMoa1810865. View

Nosaki K, Saka H, Hosomi Y, Baas P, de Castro Jr G, Reck M . Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. Lung Cancer. 2019; 135:188-195. DOI: 10.1016/j.lungcan.2019.07.004. View

Lisberg A, Cummings A, Goldman J, Bornazyan K, Reese N, Wang T . A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC. J Thorac Oncol. 2018; 13(8):1138-1145. PMC: 6063769. DOI: 10.1016/j.jtho.2018.03.035. View

Reck M, Rodriguez-Abreu D, Robinson A, Hui R, Csoszi T, Fulop A . Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. J Clin Oncol. 2019; 37(7):537-546. DOI: 10.1200/JCO.18.00149. View

Hellmann M, Ciuleanu T, Pluzanski A, Lee J, Otterson G, Audigier-Valette C . Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. N Engl J Med. 2018; 378(22):2093-2104. PMC: 7193684. DOI: 10.1056/NEJMoa1801946. View

10.

Scagliotti G, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C . Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008; 26(21):3543-51. DOI: 10.1200/JCO.2007.15.0375. View

11.

Tsao M, Kerr K, Kockx M, Beasley M, Borczuk A, Botling J . PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project. J Thorac Oncol. 2018; 13(9):1302-1311. PMC: 8386299. DOI: 10.1016/j.jtho.2018.05.013. View

12.

Nurieva R, Wang J, Sahoo A . T-cell tolerance in cancer. Immunotherapy. 2013; 5(5):513-531. PMC: 5103631. DOI: 10.2217/imt.13.33. View

13.

Carbone D, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M . First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 376(25):2415-2426. PMC: 6487310. DOI: 10.1056/NEJMoa1613493. View

14.

Meder L, Schuldt P, Thelen M, Schmitt A, Dietlein F, Klein S . Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung Cancer. Cancer Res. 2018; 78(15):4270-4281. DOI: 10.1158/0008-5472.CAN-17-2176. View

15.

Kuon J, Hommertgen A, Krisam J, Lasitschka F, Stenzinger A, Blasi M . Durvalumab in frail and elderly patients with stage four non-small cell lung cancer: Study protocol of the randomized phase II DURATION trial. Trials. 2020; 21(1):352. PMC: 7178741. DOI: 10.1186/s13063-020-04280-8. View

16.

Lee G, Lee S, Oh D, Yu D, Jeong H, Kim J . MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values. J Thorac Oncol. 2017; 12(8):1233-1246. DOI: 10.1016/j.jtho.2017.04.031. View

17.

Bassanelli M, Sioletic S, Martini M, Giacinti S, Viterbo A, Staddon A . Heterogeneity of PD-L1 Expression and Relationship with Biology of NSCLC. Anticancer Res. 2018; 38(7):3789-3796. DOI: 10.21873/anticanres.12662. View

18.

Reck M, Rodriguez-Abreu D, Robinson A, Hui R, Csoszi T, Fulop A . Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016; 375(19):1823-1833. DOI: 10.1056/NEJMoa1606774. View

19.

Garassino M, Cho B, Kim J, Mazieres J, Vansteenkiste J, Lena H . Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. Lancet Oncol. 2018; 19(4):521-536. PMC: 7771363. DOI: 10.1016/S1470-2045(18)30144-X. View

20.

Fancello L, Gandini S, Pelicci P, Mazzarella L . Tumor mutational burden quantification from targeted gene panels: major advancements and challenges. J Immunother Cancer. 2019; 7(1):183. PMC: 6631597. DOI: 10.1186/s40425-019-0647-4. View